Table 6.
Regression analysis of data from multiple logistic analyzed clinical parameters and polymorphisms in patients with hepatocellular carcinoma tumors divided into stages 0 and tumore in stages A and B, C and D according barcelona clinic liver cancer criteria
| Variables | Stage 0 e A | Estage B, C e D | OR (95%CI)1 | P |
| Pacientes n (%) | Pacientes n (%) | |||
| Alpha fetoprotein | ||||
| > 500 ng/mL | 22 (84.6) | 21 (46.7) | Reference | Reference |
| < 500 ng/mL | 4 (15.4) | 24 (53.3) | 2.66 (0.55-12.72) | 0.22 |
| Hepatitis B virus | ||||
| Absence | 25 (96.2) | 38 (84.4) | Reference | Reference |
| Presence | 1 (3.85) | 7 (15.6) | 4.06 (0.34-48.29) | 0.27 |
| Hepatitis C virus | ||||
| Absence | 12 (46.2) | 22 (48.9) | Reference | Reference |
| Presence | 14 (53.8) | 23 (41.1) | 1.43 (0.35-5.78) | 0.61 |
| Steatohepatitis | ||||
| Absence | 26 (100) | 42 (93.3) | Reference | Reference |
| Presence | 00 (00) | 3 (6.7) | 3 | 0.99 |
| Diabetes | ||||
| Absence | 18 (69.2) | 32 (71.1) | Reference | Reference |
| Presence | 8 (30.8) | 13 (28.9) | 0.25 (0.03-1.63) | 0.15 |
| Death | ||||
| No | 24 (92.3) | 17 (37.8) | Reference | Reference |
| Yes | 2 (7.7) | 28 (62.2) | 25.3 (3.67-174.38) | 0.0012 |
| MTHFR A1298C | ||||
| AA | 10 (38.5) | 22 (48.9) | Reference | Reference |
| AC/CC | 16 (61.5) | 23 (51.1) | 0.93 (0.22-3.86) | 0.92 |
| MTHFR C677T | ||||
| CC | 11 (42.3) | 17 (37.8) | Reference | Reference |
| CT/TT | 15 (57.7) | 28 (62.2) | 1.65 (0.34-7.97) | 0.53 |
| MTR A2756G | ||||
| AA | 18 (69.2) | 28 (62.2) | Reference | Reference |
| AG/GG | 8 (30.8) | 17 (37.8) | 0.78 (0.18-3.43) | 0.75 |
| MTRRA66G | ||||
| AA | 4 (15.4) | 8 (17.8) | Reference | Reference |
| AG/GG | 22 (84.6) | 37 (82.2) | 1.09 (0.16-7.30) | 0.93 |
1
OR: Odds ratio, CI: Confidence interval;
2
Statistically significant at P ≤ 0.05;
3
Could not calculate due to numerical proximity.